Unknown

Dataset Information

0

Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies.

ABSTRACT:

SUBMITTER: La Rosee F 

PROVIDER: S-EPMC7490488 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies.

La Rosée Felicitas F   La Rosée Paul P  

Acta haematologica 20200820 3

Similar Datasets

Unknown The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
| S-EPMC7282206 | biostudies-literature
Unknown The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.
| S-EPMC10457200 | biostudies-literature
Unknown Severity and 1-year cumulative incidence of COVID-19 among inpatients with haematologic malignancies.
| S-EPMC9060715 | biostudies-literature
Unknown COVID-19 Hyperinflammation: What about Neutrophils?
| S-EPMC7316488 | biostudies-literature
Unknown Immunopathology of Hyperinflammation in COVID-19.
| S-EPMC7484812 | biostudies-literature
Unknown Serum NMR metabolomics to differentiate haematologic malignancies.
| S-EPMC5966245 | biostudies-literature
Unknown Components of the Lectin Pathway of Complement in Haematologic Malignancies.
| S-EPMC7408476 | biostudies-literature
Unknown Assessment of Admission COVID-19 Associated Hyperinflammation Syndrome Score in Critically-Ill COVID-19 Patients
| S-EPMC9549159 | biostudies-literature
Unknown Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation.
| S-EPMC8811745 | biostudies-literature
Unknown Network Pharmacology Reveals That Resveratrol Can Alleviate COVID-19-Related Hyperinflammation.
| S-EPMC8463930 | biostudies-literature